Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution
View original at finance.yahoo.comTeleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown WAYNE, Pa., March 27, 2026--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Irenic's statement that 'the Board has directed the Company's advisors to refuse approaches from potential acquirors' is patently false
60% confidenceDivestitures create a more focused medical technologies leader with higher forward revenue CAGR, positioned to drive growth across core critical care and high acuity hospital market
60% confidenceIrenic grossly mischaracterizes the discussions between Teleflex and Irenic, in particular the words of Teleflex's Chairman of the Board, Dr. Stephen Klasko
60% confidenceTeleflex has not rebuffed inbounds from potential acquirers or received proposals to acquire the Teleflex RemainCo business
60% confidenceThe Board would thoroughly and thoughtfully consider any bona fide acquisition proposal in the context of the long-term value inherent in the business
60% confidenceThe Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders
60% confidenceIrenic demanded that Teleflex immediately announce a public strategic alternatives process within a week or would issue public press release calling for a sale
60% confidenceExpecting $1.8 billion of net proceeds for buyback and debt paydown from sale transactions
60% confidenceTeleflex is making progress on strategic priorities including driving durable performance and building clearer financial profile with significant improvements in margins, interest expense and adjusted earnings per share
60% confidenceCompany will maintain a disciplined capital allocation framework after completing share repurchase and debt paydown
60% confidenceThe acquisition of BIOTRONIK's Vascular Intervention business expanded coronary intervention portfolio and established global footprint in fast-growing peripheral intervention market
60% confidencePreviously announced sale transactions on track to close in second half of 2026
60% confidence